Geron discontinues Phase 3 myelofibrosis trial after survival assessment

On October 28, 2026, Geron discontinued the Phase 3 IMpactMF trial of imetelstat in patients with relapsed or refractory myelofibrosis. An independent Data Monitoring Committee concluded that the study was unlikely to meet its primary overall-survival endpoint. Geron reported no new safety signals and plans a detailed data review before sharing findings.

The decision ends Geron's current late-stage effort to expand imetelstat into this myelofibrosis population, while the commercial opportunity remains focused on its approved RYTELO uses. No efficacy results have been reported, so investors await the company's later analysis.

  • 1The IMpactMF trial enrolled 327 patients with intermediate-2 or high-risk myelofibrosis that had relapsed or was refractory to a JAK inhibitor.
  • 2Patients were randomized 2:1 to receive imetelstat or best available therapy, with imetelstat administered at 9.4 mg/kg intravenously every three weeks.
  • 3The Data Monitoring Committee said the trial was unlikely to meet its primary endpoint of overall survival.
  • 4Geron said no new safety signals were observed and that it will share a detailed analysis with the scientific community at a future date.

Sources